- Incyte (NASDAQ:INCY) and Zai Lab (NASDAQ:ZLAB) have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China.
- Under the terms of the agreement, Zai Lab will pay Incyte $17.5M up front and an additional $60M in milestone payments, as well as tiered royalties from the low to mid-twenties, with Incyte responsible for all royalties and pass-through payments to its licensing partner, MacroGenics.
- Zai Lab will receive the rights to develop and exclusively commercialize INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.
- Incyte will retain an option to assist in the promotion of INCMGA0012 in Zai Lab’s licensed territories.
- In 2017, Incyte entered into an exclusive global collaboration and license agreement with MacroGenics, for global rights to INCMGA0012.